Real-World Use of Pacritinib in Myelofibrosis: Results from the TriNetX Analysis on Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Platelets ≥50×10⁹/L at Initiation (TRIPAC)

• EHA •
• 13 June, 2026 •
• •

Consistency of Response by Baseline Platelet Count in Pacritinib-treated patients in the Real World: MY-PAC Analysis

James Rossetti, Douglas Tremblay, Abiola Oladapo, Michael Marrone, Caleb Paydar, Djibril Liassou, Sarah A. Buckley, Purvi Suthar, Adina Geprifti, Michael Vredenburg , Bruce Feinberg, Naveen Pemmaraju

Available materials

• ASCO •
• 1 June, 2026 •
• •

Treatment Patterns and Outcomes in Pacritinib-treated Patients with and higher platelet count: MY-PAC Study

Douglas Tremblay, Abiola Oladapo, Michael Marrone, Puja Aggarwal, Caleb Paydar, Djibril Liassou, Purvi Suthar, Adina Geprifti, Michael Vredenburg , Bruce Feinberg

• ASH •
• 8 December, 2025 •
• •

Treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib following a switch from ruxolitinib: The MY-PAC Study

Douglas Tremblay, Abiola Oladapo, Michael Marrone, Puja Aggarwal, Caleb Paydar, Djibril Liassou, Purvi Suthar, Adina Geprifti, Michael Vredenburg , Bruce Feinberg, James Rossetti, Naveen Pemmaraju

• ASH •
• 8 December, 2025 •
• •

Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States

Aaron T Gerds, Lindsay AM Rein, Nicole M Engel-Nitz, Michael Marrone, Jeffrey McPheeters, Abiola Oladapo, Purvi Suthar, Michael Vredenburg , Yong Zhu, Lucia Masarova